The Competition Commission of Pakistan (CCP) on Friday approved the acquisition of trademarks for the pharmaceutical product ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

The French government is looking at options including taking a public stake in the consumer health business that Sanofi is in ...

Sanofi SA is in talks to sell a 50% controlling stake in its consumer health business to Clayton Dubilier & Rice, as the ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

Sept 24 (Reuters) - Sanofi (SASY.PA), opens new tab has received two separate bids from private equity firms for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...

In France, pharmaceutical giant Sanofi has entered into talks to sell a controlling 50% stake in its consumer health business Opella to a US private equity firm. The sale is estimated at around 15 ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In our partnerships and licensing focus month, we speak with Mohammed Charki about his role at biotech Hemarina, and the company’s relationship with global drugmaker Sanofi. It’s fair to say ...

Bank of America Securities analyst Graham Parry maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €122.00. Graham Parry has given his Buy rating due ...